A continued insider selling streak without institutional buying convergence would tilt bearish; a reversal in value trend with insider buying would turn bullish.

Invalidation Risk

A clear quarter of institutional accumulation (value up, buyer count dominant) coupled with insider buying would negate the neutral call.

The above is AI-generated from public regulatory filings and summarizes historical data only. It is not investment advice and should not be used as the basis for any buy or sell decision.

Insider Trading (Form 4)

90d confidence

unique buyers

—

buy value

data as of 2026-07-16

12-Month Buy/Sell Activity

Feb 25

Aug 25

Dec 25

Mar 26

BuySell

操作	內部人	職稱	交易日	金額
賣出	Ourania Tatsis	EVP, Chief Reg. & Quality Off.	2026-07-02	$787K
賣出	Duncan Mckechnie	EVP, Chief Commercial Officer	2026-07-02	$800K
賣出	Joy Liu	EVP and Chief Legal Officer	2026-07-01	$416K
賣出	Bozic Carmen	EVP and CMO	2026-06-26	$288K
賣出	Bozic Carmen	EVP and CMO	2026-03-27	$1.05M
賣出	Bozic Carmen	EVP and CMO	2026-03-13	$1.12M
賣出	Duncan Mckechnie	EVP, Chief Commercial Officer	2026-03-11	$1.31M
賣出	Duncan Mckechnie	EVP, Chief Commercial Officer	2026-03-04	$1.16M

View all insider trades →

Form 144 Pre-Sale Notices

Filings (90d)

$5.38M

Total Est. Value

11K shares

Planned Shares

Last Filed 2026-07-02

Filer	Title/Relationship	Filing Date	Planned Shares	Est. Value
Tatsis Ourania	Officer	2026-07-02	2K shares	$787K
McKechnie Duncan	Officer	2026-07-02	2K shares	$800K
Liu Joy	Officer	2026-07-01	828 shares	$416K
Bozic Carmen	Officer	2026-06-26	596 shares	$288K
Bozic Carmen	Officer	2026-06-18	1K shares	$471K
Bozic Carmen	Officer	2026-06-15	4K shares	$1.83M
Bozic Carmen	Officer	2026-06-05	2K shares	$785K

Form 144 is a planned sale notice, not an executed transaction. Form 144 Tracker。

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

Filings (14d)

Data as of 2026-07-07

2026-07-07

Vertex Pharmaceuticals has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, with the deal expected to close in the third quarter of 2026. The acquisition is subject to shareholder approval and regulatory clearances. Crinetics's outstanding stock options and restricted stock units will also be cashed out under the terms.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding VERTEX PHARMACEUTICALS INC (VRTX)?

Major stakeholders currently include Capital World Investors ($11.3B), BlackRock, Inc. ($10.7B), Capital Research Global Investors ($9.4B). Based on the latest 13F filings, there are a total of 1698 tracked investment funds and institutions maintaining positions in VRTX.

What is the overall institutional sentiment toward VRTX recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $3.2B, driven by 817 managers accumulating shares while 707 reduced their exposure.

Which institutions have been selling or reducing their VRTX positions?

In the latest period, 598 funds trimmed their holdings, and 109 managers completely exited their positions. The aggregate reported sell value was $46.2B.

Are there any notable investors adding VRTX to their portfolios?

Yes, buying activity remains notable. 131 institutions opened new positions in {ticker}, and 686 existing holders added to their shares. The total reported buy value for the quarter amounted to $55.9B.